NOT FOR DISTRIBUTION
Header cover image

Market Cap

₹5.9b

Last Updated

2021/04/21 12:16 UTC

Data Sources

Company Financials

Executive Summary

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. More Details


Snowflake Analysis

Flawless balance sheet with outstanding track record.

Share Price & News

How has Kopran's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KOPRAN is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: KOPRAN's weekly volatility (7%) has been stable over the past year.


Market Performance


7 Day Return

19.8%

KOPRAN

4.2%

IN Pharmaceuticals

-0.8%

IN Market


1 Year Return

388.5%

KOPRAN

43.6%

IN Pharmaceuticals

62.7%

IN Market

Return vs Industry: KOPRAN exceeded the Indian Pharmaceuticals industry which returned 43.4% over the past year.

Return vs Market: KOPRAN exceeded the Indian Market which returned 60.8% over the past year.


Shareholder returns

KOPRANIndustryMarket
7 Day19.8%4.2%-0.8%
30 Day27.1%11.7%-1.7%
90 Day4.8%6.3%2.0%
1 Year394.6%388.5%45.0%43.6%65.2%62.7%
3 Year100.7%98.3%59.5%55.1%21.6%15.5%
5 Year157.7%154.5%32.6%27.7%76.9%63.3%

Long-Term Price Volatility Vs. Market

How volatile is Kopran's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kopran undervalued compared to its fair value and its price relative to the market?

10.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: KOPRAN (₹137.45) is trading below our estimate of fair value (₹162.55)

Significantly Below Fair Value: KOPRAN is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: KOPRAN is good value based on its PE Ratio (10.8x) compared to the IN Pharmaceuticals industry average (20.6x).

PE vs Market: KOPRAN is good value based on its PE Ratio (10.8x) compared to the Indian market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KOPRAN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KOPRAN is overvalued based on its PB Ratio (2.5x) compared to the IN Pharmaceuticals industry average (2.3x).


Future Growth

How is Kopran forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kopran has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Kopran performed over the past 5 years?

20.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KOPRAN has high quality earnings.

Growing Profit Margin: KOPRAN's current net profit margins (11.7%) are higher than last year (6.4%).


Past Earnings Growth Analysis

Earnings Trend: KOPRAN has become profitable over the past 5 years, growing earnings by 20.8% per year.

Accelerating Growth: KOPRAN's earnings growth over the past year (115.3%) exceeds its 5-year average (20.8% per year).

Earnings vs Industry: KOPRAN earnings growth over the past year (115.3%) exceeded the Pharmaceuticals industry 39.9%.


Return on Equity

High ROE: KOPRAN's Return on Equity (23.3%) is considered high.


Financial Health

How is Kopran's financial position?


Financial Position Analysis

Short Term Liabilities: KOPRAN's short term assets (₹2.5B) exceed its short term liabilities (₹1.4B).

Long Term Liabilities: KOPRAN's short term assets (₹2.5B) exceed its long term liabilities (₹327.9M).


Debt to Equity History and Analysis

Debt Level: KOPRAN's debt to equity ratio (28.5%) is considered satisfactory.

Reducing Debt: KOPRAN's debt to equity ratio has reduced from 68.3% to 28.5% over the past 5 years.

Debt Coverage: KOPRAN's debt is well covered by operating cash flow (77.5%).

Interest Coverage: KOPRAN's interest payments on its debt are well covered by EBIT (14.4x coverage).


Balance Sheet


Dividend

What is Kopran current dividend yield, its reliability and sustainability?

2.20%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: KOPRAN's dividend (2.33%) is higher than the bottom 25% of dividend payers in the Indian market (0.44%).

High Dividend: KOPRAN's dividend (2.33%) is in the top 25% of dividend payers in the Indian market (1.93%)


Stability and Growth of Payments

Stable Dividend: Too early to tell whether KOPRAN's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if KOPRAN's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Kopran has no CEO, or we have no data on them.


Leadership Team

Experienced Management: KOPRAN's management team is seasoned and experienced (6.8 years average tenure).


Board Members

Experienced Board: KOPRAN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Kopran Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kopran Limited
  • Ticker: KOPRAN
  • Exchange: NSEI
  • Founded: 1958
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹5.895b
  • Shares outstanding: 43.25m
  • Website: https://www.kopran.com

Number of Employees


Location

  • Kopran Limited
  • Parijat House
  • 1076, Dr. E Moses Road
  • Mumbai
  • Maharashtra
  • 400018
  • India

Listings


Biography

Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers finished dosage for...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/21 12:16
End of Day Share Price2021/04/20 00:00
Earnings2020/12/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.